Navigation Links
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema
Date:3/4/2009

- Hereditary Angioedema (HAE) and the Dawn of New Therapeutics -

EXTON, Pa., March 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its 'Teach-in' educational event for investors on Hereditary Angioedema (HAE), on Tuesday, March 10, 2009. Lectures will be provided by Anthony J. Castaldo and Janet Long, president and vice president, respectively, of the U.S. Hereditary Angioedema Association (HAEA), and Aleena Banerji, M.D., an HAE specialist at Massachusetts General Hospital.

The 'Teach-in', entitled 'Hereditary Angioedema (HAE) and The Dawn of New Therapeutics' will be held from 5:00 P.M. until 6:30 P.M. Eastern Time on Tuesday March 10, 2009.

"We are thrilled to enlist the participation of these key opinion leaders in the field of hereditary angioedema, who each day deal with the severe ramifications of HAE in their patients, families, and constituents," commented Will Roberts, ViroPharma's vice president of corporate communications. "As the proud stewards of the only approved C1 inhibitor therapy on the market, ViroPharma is committed to fostering our role as leaders in the space through the execution of essential disease awareness and investor programs."

A live audio webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website, http://www.viropharma.com. The archive of the meeting will be available through March 24, 2009.

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients wit
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
2. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. ViroPharma Provides Update on Vancocin(R)
5. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
6. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
7. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
8. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
9. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... sweetFrog ... Texas. The opening is now the 19th sweetFrog store located in the Lone Star ... list of fastest growing companies in 2014. , The store, which opened July 1 ...
(Date:7/2/2015)... ... ... swing, Americans are flocking to Canada’s many lakes to reel in their fair share of ... it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to the ... huge industry, and Americans make up the vast majority of anglers from outside of Canada. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, SIGVARIS ... for men. , For style that’s quick on its feet, men will love ... great news for men everywhere because a simple change in socks can dramatically help ...
(Date:7/2/2015)... TX (PRWEB) , ... July ... ... pressure wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on ... of development. Complete report on negative pressure wound therapy (NPWT) with 22 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies ... pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation ... on the conservative treatment of back, hip, knee and shoulder pain as well ...
Breaking Medicine News(10 mins):Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... Calif., March 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... financing facility under which it may sell up to ... Ltd. over a,24-month period. Alexza is not obligated to ... to enter into and consummate other equity and,debt financing ...
... occur , , MONDAY, March 31 (HealthDay News) -- Cerebral ... from red blood cells that have leaked out of ... over age 60 than previously believed, according to a ... higher overall prevalence of cerebral microbleeds compared to other ...
... WILMINGTON, N.C., March 31 PPD, Inc. (Nasdaq:,PPDI) ... as executive,vice president of global clinical development. In ... company,s Phase II-IV operations in,North America; Latin America; ... "Mike Wilkinson brings an exceptional resume with strong ...
... A Saint Louis University cardiologist called upon the U.S. ... strong warning it recently placed on a diagnostic tool, ... life-threatening cardiac events. , In October 2007, the ... agents, which are used to improve the quality of ...
... following was,issued today by the National Press Club:, National ... 2:00 p.m., National Press Club (Broadcast Center), ... will discuss,Quality as a Path to Improving the Cost of ... patient safety and health care products and,services company, R. Kerry ...
... By Will Arnett, Matthew Broderick, Steve Carell, Stephen, ... Kevin James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, ... The Insult Comic Dog And Many More To Be ... announced today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band ...
Cached Medicine News:Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:Small Brain Lesions More Common Than Thought in Those Over 60 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 3Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 2Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 3Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2
(Date:7/2/2015)... , July 2, 2015  The Commission for ... with ASHP, an organization that represents pharmacists in ... provider of continuing education for recertification of Certified ... of geriatric programs for this purpose.  ASHP will ... authorized providers for the CCGP Professional Development Program. ...
(Date:7/2/2015)... South Korea, July 2, 2015 ALPINION MEDICAL SYSTEMS ... E-CUBE Series ultrasound system. Developed to enhance user experience ... the E-CUBE 15 EX produces superb image quality. With ... in women,s health, general imaging, and shared service applications. ... latest in the renowned E-CUBE Series, the E-CUBE 15 ...
(Date:7/2/2015)... 25, 2015 Research and ... "Veterinary / Animal Vaccines Market by Product, Diseases ... to their offering. The global animal vaccines ... from $5,507.3 Million in 2015, at a CAGR of ... fueling market growth are growing prevalence of animal diseases, ...
Breaking Medicine Technology:Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2
... Enhance Precision and Reduce High Failure Rates in ... March 16 ICON (Nasdaq: ICLR ... services to the pharmaceutical, biotechnology and medical device ... psychiatric patient evaluation, today announced that they have ...
... Presented Results at The Sixth International Symposium on Melanoma ... Detailed Efficacy Data to be Presented at ASCO May ... Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a ... interim safety and efficacy results from the first 20 ...
Cached Medicine Technology:ICON and MedAvante Sign Alliance Agreement 2Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 2Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 3Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 4
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... for the semi-quantitative determination of specific ... serum. The results of the anti-GBM.assay ... in the diagnosis of diseases associated ... including Goodpastures Syndrome. Levels of these ...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
Medicine Products: